* Alector Inc reported a quarterly adjusted loss of 43 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -53 cents. The mean expectation of eleven analysts for the quarter was for a loss of 53 cents per share. Wall Street expected results to range from -59 cents to -47 cents per share.

* Revenue rose 68.4% to $15.34 million from a year ago; analysts expected $15.70 million.

* Alector Inc's reported EPS for the quarter was a loss of 43 cents​.

* The company reported a quarterly loss of $42.22 million.

* Alector Inc shares had risen by 12.4% this quarter and lost 34.3% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had fallen by about 0.7% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Alector Inc is $12.00 This summary was machine generated from LSEG data November 7 at 02:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.53 -0.43 Beat

Jun. 30 2024 -0.50 -0.40 Beat

Mar. 31 2024 -0.51 -0.38 Beat

Dec. 31 2023 -0.77 -0.49 Beat